Premium
Endothelin‐ 1 (ET‐1) plasma levels in multiple sclerosis (MS) patients
Author(s) -
JANKOWSKALECH I,
BIK Z,
WOLINSKA E,
TERELAKBORYS B,
GRABSKALIBEREK I,
PALASIK W
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.2266.x
Subject(s) - multiple sclerosis , medicine , endothelin 1 , plasma levels , endothelin receptor , significant difference , gastroenterology , immunology , receptor
Purpose The aim of this study was to estimate endothelin‐ 1 (ET‐1) plasma level in multiple sclerosis patients. Methods Material was 49 patients (13 males, 36 females, mean age: 40 year, range: 22‐ 62 years) suffering from multiple sclerosis according to McDonalds rule. The healthy controls consisted of 3 males and 28 females (mean age: 38 year, range: 19‐ 61 years). The protocol was approved by the Ethical Committee of the Postgraduate Medical Education Centre in Warsaw, Poland. Endothelin‐ 1 (ET‐1) plasma levels were determined by ELISA Test (Immuno‐ Biological Laboratories. Co, Japan with tenderness : 8 fmol/ml). Statistical analysis were performed using the U‐ Mann‐ Withney test. Results Endothelin‐ 1 (ET‐1) plasma levels were significantly decreased in MS patients when compared to age matched controls (P= 0.0075). Conclusion Statistically significant ET‐1 plasma levels difference between examined patients and controls indicates, that vascular dysregulation may exists in MS patients. The outcomes will be discussed.